The U.S. Government and Accountability Office (GAO) is examining 340B contract pharmacy arrangements, although we do not yet know the purpose of the GAO’s review.  The GAO is the investigative arm of Congress charged with examining matters relating to the receipt and payment of public funds.  It typically issues final reports summarizing the results of its reviews and providing recommendations for improvement.  The last time GAO issued 340B-specific reports was in 2015, when GAO examined 340B Program oversight and Medicare Part B drug spending at 340B hospitals.